logo
  • Resources by Tumor Type
  • Provider Resources
    • Care Step Pathways
    • Continuing Education
    • Provider Toolkits
    • Healthcare Disparities
      • Primer
      • Videos
    • ctDNA Testing for Response Monitoring
    • News
  • Patient/Caregiver Resources
    • Patient Action Plans
    • Caregiver Resource
    • Options for Stage IV Melanoma
    • Options for Stage III Melanoma
    • Options for Stage II Melanoma
    • Non-Invasive Evaluation Tools (Melanoma)
    • ctDNA Testing Handout
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • Videos
    • HCP Videos
    • Patient Videos
  • Resources by Tumor Type
  • Provider Resources
    • Care Step Pathways
    • Continuing Education
    • Provider Toolkits
    • Healthcare Disparities
      • Primer
      • Videos
    • ctDNA Testing for Response Monitoring
    • News
  • Patient/Caregiver Resources
    • Patient Action Plans
    • Caregiver Resource
    • Options for Stage IV Melanoma
    • Options for Stage III Melanoma
    • Options for Stage II Melanoma
    • Non-Invasive Evaluation Tools (Melanoma)
    • ctDNA Testing Handout
  • International Resources
    • Australia
    • Canada
    • France
    • Germany
    • Italy
    • Portugal
    • Spain
    • UK
  • Videos
    • HCP Videos
    • Patient Videos
Avatar photo
  • Profile
  • Topics Started
  • Replies Created
  • Engagements
  • Favorites

Topics Engaged In

Viewing 6 topics - 1 through 6 (of 6 total)
    • Topic
    • Voices
    • Posts
    • Last Post
    • hepatotoxicity

      Started by: yael silman in: Side-effect management

    • 5
    • 6
    • February 23, 2018 at 5:48 pm

      Mollie Reed

    • Adjuvant pembrolizumab

      Started by: LisaTushla in: Expectations for therapy

    • 4
    • 4
    • February 19, 2018 at 10:50 pm

      Suzanne McGettigan

    • Infusion times

      Started by: Avatar photoLisa Kottschade in: Dosing and administration

    • 8
    • 11
    • February 15, 2018 at 3:41 pm

      Lisa Kottschade

    • How would you manage?

      Started by: Avatar photoKrista Rubin in: Side-effect management

    • 4
    • 4
    • January 23, 2018 at 8:51 pm

      Brianna Hoffner

    • Dose reductions with BRAF/MEK inhibitors

      Started by: LisaTushla in: Dosing and administration

    • 3
    • 3
    • January 22, 2018 at 11:28 pm

      Suzanne McGettigan

    • High copays

      Started by: LisaTushla in: Reimbursement

    • 2
    • 2
    • January 22, 2018 at 11:21 pm

      Suzanne McGettigan

  •  

Viewing 6 topics - 1 through 6 (of 6 total)

Login

Log In
Register Lost Password

Latest Activity

  • New BRAF/MEK inhibitors coming to market
    topic by Lisa Kottschade
    March 1
    in Dosing and administration
  • Adjuvant Immunotherapy in stage IIIA patients
    topic by Lisa Kottschade
    March 1
    in Expectations for therapy
  • Influenza and Tamiflu and Immunotherapy
    reply by Kathleen Madden
    February 25
    in Other
  • ASCO/NCCN guidlines now out
    reply by Mollie Reed
    February 23
    in Side-effect management
  • hepatotoxicity
    reply by Mollie Reed
    February 23
    in Side-effect management
© 2023 ImmunoHub.org. All rights reserved.
  • About
  • Terms
  • Privacy
  • Contact